| Document |
Document Title |
|
WO/1990/009164A1 |
A composition for topical application in order to induce and promote hair growth and to reduce hair loss contains, in a physiologically acceptable alcohol-based solvent medium, at least 7-alpha-(acetylthio) 4', 5'-dihydrospiro[androst 4-...
|
|
WO/1990/008315A1 |
Ginsenosides Rb1 and Rg1 enhance the availability of acetylcholine in the cortical and hippocampal regions of the brain and alleviate the symptoms of Alzheimer-type senile demential. The Rb1 or Rg1 may be administered together with a met...
|
|
WO/1990/003184A1 |
The invention claims an iscom matrix which is not a lipid vesicle comprising at least one lipid and at least one saponim but no intentional antigenic determinants and optionally also adjuvants for use as an immunomodulating agent, medici...
|
|
WO/1990/003385A1 |
New 11beta-phenyl-14betaH-steroids of general formula (I), where Z is an oxygen atom or the hydroxyimino-grouping N ~ OH, and M and N are either jointly a second compound or L is a hydrogen atom and M is an alpha-permanent hydroxy group ...
|
|
WO/1990/000174A1 |
The invention concerns 13-Alkyl-11beta-phenylgonanes of general formula (I), wherein Z, R1, R2, R3 and R4 have the meaning given, a process for their preparation, pharmaceutical preparations containing these compounds, and their use for ...
|
|
WO/1989/003839A1 |
The invention relates to the field of chemistry and more particularly to the field of therapeutic chemistry. Its specific subject matter concerns compounds of general formula (I), in which R is a hydrogen atom, a lower alkyl, methoxymeth...
|
|
WO/1988/009336A1 |
Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure ...
|
|
WO/1988/007545A1 |
Pregnane derivatives represented by general formula (I) (wherein A1 represents a hydrogen atom or a hydroxy group, A2 represents a substituent such as a hydroxy group when A1 represents a hydrogen atom, or A2 represents a hydrogen atom w...
|
|
WO/1988/007050A1 |
Process for the production of (+)-bicyclo-[3.3.0]octane-3-on-2-carboxylic acid steroid esters having the formula (I), in which X represents oxygen or the -O-(CH2)n-O- or the -O-CH2-C(CH3)2-CH2-O- residue; n represents 2 or 3; R2 represen...
|
|
WO/1988/002252A1 |
A unique set of compositions of matter characterized by including defined active agents covalently bonded to carbonium ion base groups, as well as the method of creating the compositions. The covalently bonded compositions include base g...
|
|
WO/1987/006706A1 |
Qualitative and quantitive electrochemiluminescent assays for analytes of interest present in multicomponent liquids. These methods comprise contacting a sample with a reagent labeled with an electrochemiluminescent chemical moiety and c...
|
|
WO/1987/005028A1 |
Compounds of formula (I), wherein one X is COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; remaining X's are H, F, CH3, OH, COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; Y is (i1), (i2), (i3), (i4), or (i5); R is H, alkyl of 1-5 ca...
|
|
WO/1987/002672A1 |
Novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of formula (I), wherein R15 is = O or -OH; wherein R23 with R10 forms a cyclic phosphate of formula (II) or wherein R23 is...
|
|
WO/1986/002078A1 |
New 24-homo-vitamin D compounds, methods for preparing the same and novel intermediate compounds. The compounds are characterized by vitamin D-like activity of the order of 1alpha,25-dihydroxyvitamin D3, the recognized circulating hormon...
|
|
WO/1986/001208A1 |
Stereoisometrically pure DELTA2 compound of formula (I) wherein R1 is hydrogen or -(C=O)-R2, wherein R2 is an organic substituent selected from the group consisting of alkyls, alkenyls, alkynyls, cycloalkyls, cycloalkylalkylenes, haloalk...
|
|
WO/1985/000818A1 |
New derivative of vitamin D, 23,23-difluoro-25-hydroxycholecalciferol, a method for preparing said compound and various new intermediates utilized in such process. The compound is characterized by vitamin D-like activity as evidenced by ...
|
|
WO/1985/000819A1 |
New derivative of vitamin D, 23,23-difluoro-1,25-dihydroxycholecalciferol. The compound is characterized by vitamin D-like activityas evidenced by its ability to increase intestinal calcium transport. It is further characterized by its r...
|
|
WO/1984/004041A1 |
A colon-specific drug delivery system based on the use of a synthetic drug glycoside prodrug composition which, when ingested by a mammal, undergoes reaction with glycosidases produced by colonic microflora to release a free drug capable...
|
|
WO/1984/001155A1 |
Hydroxylated derivatives of vitamin D2., processes for preparing such compounds, intermediates utilized in such processes and certain isotopically labelled vitamin D2 compounds. The vitamin D2 derivatives would find application in the tr...
|
|
WO/1983/003604A1 |
Process for preparing substitued polycyclo-alkylidene polycyclo-alkanes, such as substituted adamantylidene adamantanes, and the corresponding epidioxy compounds, in which polycyclo-alkylidene polycyclo-alkanes are halogenated with an N-...
|
|
WO/1983/003099A1 |
The invention relates to products having the general formula I, wherein R1 is thienyl or phenyl optionally substituted, furyl, cycloalkyl, naphtyl, phenyl-phenyl, alkyl or alkenyl; R2 is methyl or ethyl; R3 is H, OH, alkyl, alkenyl, opti...
|
|
WO/1982/003396A1 |
Novel cundurango glycoside compounds represented by the following general formula: (FORMULA) process for their preparation from an extract of Marsdenia cundurango Reichenbach fil., use of the compound or composition containing it as an a...
|
|
WO/1982/000465A1 |
Methods for preparing the various isomeric forms of 25-hydroxyvitamin D3-26, 23-lactone utilizing cyanohydrin formation with readily prepared steroid materials followed by actinic radiation of the products and recovery of the desired 25-...
|
|
WO/1982/000294A1 |
5(Beta)-hydroxy-(Alpha)6-steroid derivatives having the general formula (FORMULA) wherein R1 represents a hydrogen atom, an acyl, lower alkyl or tetrahydropyranyl residue and R2, R3 each a hydrogen atom or in common a methylene residue a...
|
|
WO/1981/002577A1 |
Novel cundurango glycosides represented by the following general formula (1), a process for preparing them from an extract of Marsdenia cundurango Reichenbach fil. of potato family, and the use of a compound or composition containing the...
|
|
WO/1981/002298A1 |
New derivative of vitamin D, 25-hydroxy-26,26,26,27,27,27-hexafluoro cholecalciferol and process for preparing the same. The compound is characterized by vitamin D-like activity in their ability to increase intestinal calcium transport, ...
|
|
WO/1980/002502A1 |
New vitamin D derivatives as well as new intermediate compounds derived during the processes for preparing such new derivatives. The new derivatives have been identified as 1(Alpha)-hydroxy-25-keto-27-nor-vitamin D3 and its acylates. 1(A...
|
|
JP2024040444A |
[Problem] To provide a method for treating a disease. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof [where n, R19,R5,R3a,R6a,R6b,R1,R2a,R2b,R4a,R4b,R7a,R7b,R11a,R11b,R12a
,R12b,R17...
|
|
JP2024028631A |
[Problem] To provide oxysterols and methods for using the same. [Solution] Formula (I): and pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof are provided, wherein R2,R3,R4,R5, and R6is as defined herein. ...
|
|
JP7391918B2 |
Disclosed herein are compounds having structural Formula (I), or salts thereof. These compounds are useful as sweet tasting agents and/or sweetness enhancers. Also disclosed are compositions comprising the present compounds and methods o...
|
|
JP7382946B2 |
The present invention provides host cells and methods for making mogrol glycosides, including Mogroside V (Mog. V), Mogroside VI (Mog. VI), Iso-Mogroside V (Isomog. V), and glycosylation products that are minor products in Siraitia grosv...
|
|
JP2023126904A |
To provide new oxysterols that modulate an NMDA receptor for the prevention and treatment of conditions associated with the NMDA expression and function.The invention provides compounds according to Formula (I) in the figure, and pharmac...
|
|
JP7327937B2 |
[Problem] The purpose of the present invention is to provide a new method for producing a cycloastragenol analog from astragaloside IV. {Solution] A method for producing a cycloastragenol analog that includes a contact step that brings a...
|
|
JP2023063535A |
The present invention relates to oxysterols and methods of using them. [Solution] Formula (A): and pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, R5, R6and RG.is as defined here...
|
|
JP2023514873A |
The present application relates to novel compounds that are prodrugs of brexanolone, ganaxolone, and duranolone, pharmaceutical compositions comprising one or more of the compounds disclosed herein and salts thereof, and pharmaceutically...
|
|
JP2023509798A |
The invention of the present disclosure is directed to novel structural neuroactive steroids (NAS). The invention is also directed to pharmaceutical compositions comprising neuroactive steroids (NAS) and salts thereof. The pharmaceutical...
|
|
JP2023022187A |
To provide compositions and methods for treating CNS disorders.Described herein are neuroactive steroids of the formula (II) in the figure or pharmaceutically acceptable salts thereof. Such compounds are supposed, in certain embodiments,...
|
|
JP7220931B2 |
The present invention relates to a crystalline form of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(aceto
xymethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,
4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H...
|
|
JP2022130668A |
To provide substituted oxysterols useful for preventing and/or treating a broad range of disorders.The invention provides compounds according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions t...
|
|
JP7112331B2 |
Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated use...
|
|
JP2022107795A |
To provide compounds useful for the prevention and treatment of a variety of conditions.Provided herein are compounds according to formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; in the...
|
|
JP7083394B2 |
The invention discloses a panaxadiol glycoside derivative and a preparation method and application thereof. Such compounds show strong anti-inflammatory effects in vitro and in animal model experiments, and thus can be used to prepare an...
|
|
JP2022526205A |
This disclosure generally describes compound isomogloside IV.EWith respect to various formulations and uses of. In some embodiments, the present disclosure is isomogloside IV.ETo provide a composition containing. In some embodiments, the...
|
|
JP2022526055A |
The present invention comprises a compound having structural formula (I) or a salt or solvate thereof, wherein R1 to R9 are as defined herein. These compounds are useful as sweet flavor modifiers. The invention also includes a compositio...
|
|
JP2022075974A |
To provide C17, C20 and C21 substituted neuroactive steroids and their methods of use.Described herein are neuroactive steroids or pharmaceutically acceptable salts thereof. Such compounds are expected, in certain embodiments, to behave ...
|
|
JP2022525490A |
Various embodiments presented herein relate to methods of producing food ingredients, flavors, and sweeteners from extracts of plants containing mogrosides such as Luo Han Guo (Siraitia grosvenori). Also provided herein are formulations ...
|
|
JP2022069555A |
To provide oxysterols and methods of use thereof.The present invention provides compounds according to a Formula (I) in the figure and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In the formula, R2...
|
|
JP2022523775A |
The present invention generally relates to novel compounds for therapeutic use. In particular, the present disclosure relates to novel tetracyclic compounds useful in the treatment of cancer, especially castration-resistant prostate canc...
|
|
JP2022521762A |
Mogrosides, including non-glucose glycosides, are provided herein. Compositions comprising consumables containing the novel mogrosides described herein are also provided.
|
|
JP7049313B2 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
